Enrolling Now

Enrolling Now

Subcutaneous Medication for HbA1c 

  • A study  to evaluate a subcutaneous medication in participants with T2D on a stable dose of Tirzepatide or Semaglutide who failed to achieve HbA1c goal.

    • No Type 1 Diabetes

    • Not on insulin

    • 18-75 years of age

    • T2D with HbA1c >7.5% to <10.5%

    • BMI of >27 kg/m2, with stable body weight for at least 3 months.

    • Have been on stable dose of either injectable semaglutide or tirzepatide for >3 months

    Further qualifications may apply.

  • Gain access to cutting-edge medications and treatments before they are widely available.

    Our expert team is under the guidance of renowned endocrinologist, Dr. Anastasios Manessis.

    We are highly focused on patient well-being and the highest ethical standards in clinical research.

A syringe with a blue label marked 1 mg, resting on a box of allergy injection solution.

Think you may qualify? Fill out this form and a member of our medical research team will be in touch shortly with more information.